ADTX · As filed with the SEC

Aditxt cash flow statement, by fiscal year

The statement as Aditxt presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Cash Flows · USD

USD	FY2025 Year ended Dec 31, 2025	FY2024 Year ended Dec 31, 2024	FY2023 Year ended Dec 31, 2023	FY2022 Year ended Dec 31, 2022	FY2021 Year ended Dec 31, 2021	FY2020 Year ended Dec 31, 2020	FY2019 Year ended Dec 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	—	—	—	—	—	(9,149,227)	(5,827,728)
Net loss	(42,787,043)	(35,020,058)	(32,390,447)	(27,649,876)	(46,371,364)	—	—
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	473,311	33,071	1,402,018	3,131,368	4,640,681	3,188,840	3,698,422
Depreciation expense	—	—	—	—	—	17,773	—
Stock-based compensation from asset purchase	10,000	6,712,663	—	—	—	—	—
Depreciation expense	269,271	613,918	435,027	428,977	369,236	—	—
Amortization of intangible assets	3,333	3,333	107,556	107,000	107,000	—	—
Amortization of debt discount	—	—	—	1,533,048	—	—	—
Amortization of debt discount	—	—	2,821,629	—	1,845,358	—	—
Amortization of debt discount - note payable	1,706,697	3,174,920	—	—	—	300,000	—
Modification of options	—	—	—	—	—	—	533,311
Amortization of debt discount - note receivable	(220,689)	—	—	—	—	—	—
Loss on note exchange agreement	—	208,670	—	—	—	—	—
Modifications of warrants as debt issuance costs	—	376,901	—	—	—	—	—
New principal from extension of notes, net of debt discount	—	451,974	—	—	—	—	—
Change in fair value of derivative liability	(14,515)	(414,501)	—	—	—	—	—
Change in fair value of Evofem warrants	(2,806,983)	—	—	—	—	—	—
Impairment of Evofem F-1 preferred stock	23,766,209	—	—	—	—	—	—
Disposal of fixed assets	—	3,000	—	—	—	—	—
Gain on note exchange agreement	—	—	(51,712)	—	2,500,970	—	—
Impairment on notes receivable	—	—	—	543,938	14,500,000	—	—
Disposal of fixed assets	—	—	—	6,976	—	—	—
Bargain purchase gain from purchase of Evofem convertible notes	(328,071)	—	—	—	—	—	—
Impairment of fixed assets	412,005	—	—	—	—	—	—
Changes in operating assets and liabilities:
Accounts receivable	43,435	364,891	119,635	(36,767)	(89,844)	—	—
Prepaid expenses	(613,983)	214,011	279,479	23,884	(312,460)	(147,642)	—
Deposits	—	—	248,956	(438,117)	(306,954)	—	—
Deposits	26,086	18,738	—	—	—	(72,296)	—
Inventory	5,471	734,257	204,591	(455,396)	(494,697)	—	—
Accounts payable and accrued expenses	(5,632,893)	5,095,091	6,646,457	412,959	1,333,930	(1,483,180)	601,607
Accrued compensation to related parties	—	—	—	—	—	124,728	530,036
Settlement liability	—	667,000	1,600,000	—	—	—	—
Net cash used in operating activities	(25,688,359)	(16,762,121)	(18,576,811)	(22,392,006)	(22,278,144)	(7,221,004)	(464,352)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	—	—	—	(367,079)	(1,015,752)	(170,629)	—
Tenant improvement allowance receivable	—	—	—	125,161	(287,018)	—	—
Notes receivable and accrued interest	—	—	—	—	(15,002,521)	—	—
Purchase of fixed assets	(13,743)	—	(14,407)	—	—	—	—
Investment in convertible notes receivable and warrants	(2,425,000)	—	—	—	—	—	—
Investment in Evofem F-1 preferred stock	—	(5,000,000)	—	—	—	—	—
Net cash used in investing activities	(2,438,743)	(5,000,000)	(14,407)	(241,918)	(16,305,291)	(170,629)	—
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible note payable	—	—	—	—	5,000,000	375,000	50,000
Proceeds from note payable - related party	—	—	—	80,000	—	—	—
Proceeds from notes payable, related party	678,000	467,000	1,062,523	—	—	—	10,000
Proceeds from notes and convertible notes payable, net of offering costs	1,191,018	4,149,153	7,903,445	—	—	—	—
Repayments of note payable - related party	—	—	(687,523)	—	—	(45,000)	(42,502)
Repayments of note payable, related party	(793,000)	(727,000)	—	(3,206,887)	(315,790)	—	—
Sale of Series B Preferred shares to related party	—	—	—	20,000	—	—	—
Redemption of Series B Preferred shares to related party	—	—	—	(20,000)	—	—	—
Repayments of note payable	(6,613,882)	(5,287,942)	(3,152,488)	(80,000)	—	(670,600)	(15,500)
Proceeds from notes and convertible notes payable, net of offering costs	—	—	—	2,795,000	(526,460)	—	—
Series C Preferred Shares	—	—	1,000	—	—	—	—
Series C Preferred Shares	—	—	(1,000)	—	—	—	—
Common stock, preferred stock, and warrants issued for cash, net of issuance costs	44,128,225	21,166,343	—	—	—	—	—
Cash from subscription receivable	1,108,751	4,335,877	—	—	—	—	—
Payments on financing on fixed asset	—	—	(262,160)	(400,491)	(598,976)	—	—
Cash paid on extinguishment of note payable	—	—	—	—	(1,200,000)	—	—
Proceeds from exercises of warrants	—	1,246,490	1,000	1,109,574	3,727,285	210,544	—
Financed Asset	—	—	—	—	—	(58,475)	—
Redemptions of C-1 preferred stock	—	(2,851,839)	—	—	—	—	—
Redemptions of D-1 preferred stock	—	(32)	—	—	—	—	—
Redemptions of A-1 preferred stock	(308,000)	—	—	—	—	—	—
Redemptions of C-1 preferred stock	(8,898,442)	—	—	—	—	—	—
Net cash provided by financing activities	30,492,670	22,498,050	15,919,680	17,530,503	35,954,670	17,888,369	352,733
NET INCREASE (DECREASE) IN CASH	—	—	—	—	—	10,496,736	(111,619)
CASH AT BEGINNING OF PERIOD	—	—	—	—	10,500,826	4,090	115,709
CASH AT END OF PERIOD	—	—	—	—	—	10,500,826	4,090
NET DECREASE IN CASH	—	—	—	(5,103,421)	(2,628,765)	—	—
NET INCREASE IN CASH	2,365,568	735,929	(2,671,538)	—	—	—	—
CASH AT BEGINNING OF PERIOD	833,031	97,102	2,768,640	7,872,061	10,500,826	—	—
CASH AT END OF PERIOD	3,198,599	833,031	97,102	2,768,640	7,872,061	—	—
Common stock and warrants issued for cash, net of issuance costs	—	—	11,054,883	17,233,307	29,868,611	18,500,039	470,177
Offering costs	—	—	—	—	—	(423,139)	(119,442)
Supplemental cash flow information:
Cash paid for interest expense	—	—	—	—	15,789	—	—
Cash paid for interest expense	—	—	—	753,038	—	—	—
Cash paid for interest	2,465,546	1,235,640	2,726,020	—	—	5,842	—
NONCASH INVESTING AND FINANCING ACTIVITIES:
Liabilities assumed for common stock	—	—	—	—	—	11,980	189,625
Issuance of shares for the settlement of notes payable	—	—	—	—	5,749,922	—	—
Lease liability recognized from right of use asset	—	—	—	—	3,131,388	1,191,985	—
Issuance of shares for the conversion of notes payable	—	500,000	—	—	—	—	—
Debt discount from shares issued as inducement for note payable	—	1,576,431	—	—	—	—	—
Shares issued for debt offering costs	—	—	354,838	—	—	—	—
Warrant modification	—	5,907,011	319,871	—	—	—	—
Issuance of shares in asset purchase	—	266,448	—	—	—	—	—
Shares issued for settlement	—	1,600,000	—	—	—	—	—
Shares issued for settlement	—	—	—	80,000	—	125,000	—
Issuance of units for the settlement of accrued compensation and accounts payable	—	—	—	—	—	1,222,025	—
Original offering discount on convertible note payable	—	—	—	—	1,000,000	300,000	—
Debt discount from warrants issued with convertible note payable	—	—	—	878,622	1,322,840	—	—
Debt discount from warrant consideration for convertible debt offering costs	—	—	—	—	231,316	—	—
Liability recognized for financed assets	—	—	—	—	821,862	646,063	—
Reduction in exercise price of warrants	—	—	—	—	102,267	—	—
Shares issued for debt offering costs	—	—	—	96,030	—	321,000	—
Conversion of preferred shares	—	—	—	—	—	1,250	—
Warrant modification	—	—	—	37,677	—	—	—
Deferred issuance costs	—	—	—	50,000	—	—	—
Return of notes payable from Evofem merger agreement	—	11,174,426	—	—	—	—	—
Issuance of shares of Pearsanta Common Stock for IP	—	—	10,000	—	—	—	—
Assumption of notes payable from Evofem merger agreement	—	—	11,173,750	—	—	—	—
Series A-1 Preferred shares issued for exchange agreement	—	—	22,277,233	—	—	—	—
Accrued intertest rolled into notes payable	—	—	701,315	—	—	—	—
Series B-2 Preferred shares issued in note exchange agreement	—	—	2,686,306	—	—	—	—
Accrued interest rolled into notes payable	33,752	538,223	—	—	—	—	—
Exchange of warrants for Series C-1 convertible preferred stock	—	6,000,000	—	—	—	—	—
Settlement of liability for Series C-1 Convertible Preferred Stock	—	667,000,000,000	—	—	—	—	—
Derivative liability from conversion feature on preferred stock	—	429,018	—	—	—	—	—
ELOC payable	328,071	—	—	—	—	—	—
Series C-1 redemption payable	237,498	1,354,774	—	—	—	—	—
ELOC commitment fee stock payable	2,250,000	2,250,000	—	—	—	—	—
Loan in escrow	2,000,000	—	—	—	—	—	—
Reclassification of series A-1 preferred shares to liabilities	517,444	—	—	—	—	—	—
Write off of financed asset	147,823	—	—	—	—	—	—
Initial recognition of lease liability and right of use asset	800,359	—	—	—	—	—	—

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.